Skip to content

The time and spectrum heterogeneity of microRNAs regulation after autologous platelet gel treatment to diabetic foot ulcers

The time and spectrum heterogeneity of microRNAs regulation after autologous platelet gel treatment to diabetic foot ulcers

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15006266
Enrollment
Unknown
Registered
2015-02-01
Start date
2015-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot

Interventions

APG treatment group :APG plus standard treatment
controlled group :standard treatment

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Diabetic patients over 18 years of age, with at least one foot ulcer, which did not improve significantly after at least two-week ulcer standard treatments were candidates; Systemic and local infection, especially osteomyelitis, should be appropriately treated; The inclusion criteria provided further requirements: ankle-brachial index (ABI) value >0.6; fasting and 2-hour postprandial glucose =8 and 11 mmol/l respectively; platelet count >50*10^9/L; Hb >90g/L; no severe systemic diseases (cardiac or pulmonary failure, hepatic or renal insufficiency, hematological abnormality, mental disease, malignant disease and so on); informed consent been signed.

Exclusion criteria

Exclusion criteria: Patients aged <18 years or with non-diabetic, such as malignant, ulcers were excluded. Exclusion criteria also refers to: uncontrolled systemic and local infection; platelet count <50*10^9/L; Hb <90g/L; history of severe systemic disease (severe miocardial or cerebral infarction, arrhythmia, cardiac insufficiency (grade III-IV according to New York Heart Association), acute exacerbations of chronic obstructive pulmonary disease, pulmonary heart disease, hepatic or renal insufficiency failing to respond to aggressive medical treatments) within the past 3-6 months; prescribed with systemic treatment of corticosteroids, immunosuppressive agents, radiation therapy, or chemotherapy within 3 weeks before screening; mental diseases with broken behavioral competence and compliance; pregnant or nursing women; Other conditions assessed by the investigators not appropriate for participating in this trail.

Design outcomes

Primary

MeasureTime frame
miRNA;MMPs;TIMPs;

Secondary

MeasureTime frame
TGF beta1;TcPO2;histological examination;wound area reduction rate;

Countries

China

Contacts

Public ContactXingwu Ran
ranxingwu@163.com+86 028-85403107

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026